Cellectar Biosciences, Inc. — Director's Dealing 2014

Aug 22, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2014-08-20

Reporting Person: NEIS JOHN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-08-20	Common Stock, par value $0.00001 per share	P	130000	$3.75	Acquired	493715	Indirect
2014-08-20	Common Stock, par value $0.00001 per share	P	138711	$3.75	Acquired	632426	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-08-20	Stock Purchase Warrant (right to buy)	$4.68	P	130000	Acquired	2019-08-20	Common Stock (130000)	Indirect
2014-08-20	Convertible Debenture (right to buy)	$10.00	S	50000	Disposed	2016-02-06	Common Stock (50000)	Indirect
2014-08-20	Stock Purchase Warrant (right to buy)	$4.68	P	138711	Acquired	2019-08-20	Common Stock (138711)	Indirect

Footnotes

F1: These securities are held by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

F2: These securities were issued in consideration of the tender to the issuer by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership of convertible debentures with an aggregate principal amount and accrued interest equal to the purchase price of the securities.

F3: These securities were tendered to the issuer by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership in consideration of the purchase of shares of Common Stock and Stock Purchase awards as described elsewhere in this Form 4.